On January 4, 2018 Sangamo Therapeutics, Inc. (NASDAQ: SGMO) reported that Dr. Sandy Macrae, CEO of Sangamo, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th at 4:00 p.m. PT. Dr. Macrae’s presentation will be followed by a separate Q&A session starting at 4:30 p.m. PT (Press release, Sangamo Therapeutics, JAN 4, 2018, View Source [SID1234522912]). The conference is being held in San Francisco, CA from January 8-11, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation and Q&A session will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

On January 4, 2018 AvantGen reported the successful completion of a first cancer therapeutic antibody discovery program for Tanabe Research Laboratories USA, Inc. (TRL) and the initiation of a second program (Press release, AvantGen, JAN 4, 2018, View Source [SID1234522916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the collaboration, AvantGen is responsible for generating novel antibodies to specified cancer targets using its proprietary human antibody yeast display technology platform. TRL has worldwide rights to develop and commercialize antibodies discovered by AvantGen. AvantGen receives upfront payments and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.

"AvantGen’s antibody discovery and optimization services have been extensively validated against hundreds of targets primarily through numerous NIH SBIR I and II funded projects. Since the recent introduction of our new, state-of-the-art human antibody discovery and optimization platform, this second project with TRL represents the fifteenth de novo antibody discovery project we have initiated specifically for corporate partners," said Xiaomin Fan, Ph.D., founder and president of AvantGen. "The platform utilizes advantageous technologies, including a robust yeast display system, large natural human antibody database and fully human antibody libraries, for the generation of antibodies to meet challenging design goals for therapeutic, diagnostic and research tool purposes."

"The therapeutic antibody discovery program conducted by AvantGen was highly collaborative and was accomplished faster than expected, without the need to further optimize the antibodies in order to meet TRL’s design goals," said Roland Newman, Ph.D., chief scientific officer for TRL. "We look forward to working together on the second program and others in the future."

On January 4, 2019 Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing tumor-directed immunotherapies, reported that the company is scheduled to present at the 10th Annual Biotech Showcase conference held 8-10 January, 2018 in San Francisco, US (Press release, Alligator Bioscience, JAN 4, 2018, View Source [SID1234538682]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Per Norlén will give an update on the company’s clinical stage project ADC-1013, out-licensed to Janssen Biotech Inc., as well as the near-clinical bispecific antibody ATOR-1015 and the preclinical projects ALG.APV-527 and ATOR-1017.

The presentation will take place on 8 January, at 10:30 a.m. PST /8 Jan 7:30 p.m. CET. The audio and slide presentation will be webcasted live and can be accessed via the Alligator web site. To access the presentation, live and replay, please go to View Source;tp_key=101995f0f8.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
E-mail: [email protected].

The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CET on 4 January 2018.

On January 4, 2018 Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported that it will host a live audio webcast at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Teva, JAN 4, 2018, View Source;p=RssLanding&cat=news&id=2324950 [SID1234522913]). Kåre Schultz, President & CEO will present on Monday, January 8, 2018 at 9:30 AM PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

What:

Teva Presentation at the 36th Annual J.P. Morgan Healthcare Conference

Who:

Kåre Schultz, President & CEO
Teva Pharmaceutical Industries Ltd.

When:

Monday, January 8, 2018 at 9:30 AM PST

Where:

www.ir.tevapharm.com

How:

Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s website.

On January 4, 2018 Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) reported an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology (Press release, Illumina, JAN 4, 2018, View Source [SID1234522917]). The collaboration is a significant step toward China Food and Drug Administration (CFDA) review and approval, and serves as a starting point to deliver precision medicine to patients throughout China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Illumina and KingMed Diagnostics will partner to co-develop an integrated NGS system that provides cost-effective and ready-to-use in-vitro diagnostic (IVD) assays for molecular oncology and hereditary cancer testing. The new system is based on Illumina’s MiniSeq System and related sequencing consumables, integrated with KingMed Diagnostics’ proprietary testing components, which include library preparation kits and analysis software.

The integrated system can reach cancer patients across China via KingMed Diagnostics’ extensive clinical network that serves more than 8,000 Class 2 and Class 3B hospitals.

"KingMed Diagnostics’ motivation is to improve diagnosis and treatment for the more than 4 million new cancer patients identified in China each year. Our mission is to bring state-of-the-art technology to Chinese patients by enhancing their standard of care and improving their outcomes," said Professor Yaoming Liang, Chairman and CEO of KingMed Diagnostics. "Illumina is the ideal collaborator because they have a proven track record of working with multiple domestic companies in China, in addition to being the first company with a U.S. FDA-cleared, next-generation sequencing instrument."

"KingMed Diagnostics is one of the leading independent clinical laboratory service providers in China, and as such, we are excited to partner with them to help customize the MiniSeq System under CFDA requirements for clinical oncology applications," said Garret Hampton, Ph.D., Executive Vice President of Clinical Genomics at Illumina.

"This agreement is a clear demonstration of our commitment to working with broader clinical testing service providers in China who want to develop and commercialize IVDs based on NGS," said Ruilin Zhao, Ph.D., Illumina’s Vice President and General Manager of Greater China. "As we continue to expand our clinical partner networks, we are focused on providing the best healthcare solutions to patients throughout China."